UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV

Leukemia, 2015-05, Vol.29 (5), p.1123-1132

2015

Volltextzugriff (PDF)

Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)

Leukemia, 2012-09, Vol.26 (9), p.2096-2102

2012

Volltextzugriff (PDF)

Additional mutations in SRSF2, ASXL1 and/or RUNX1 identify a high-risk group of patients with KIT D816V+ advanced systemic mastocytosis

Leukemia, 2016-01, Vol.30 (1), p.136-143

2016

Volltextzugriff (PDF)

Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IV

Leukemia, 2016-06, Vol.30 (6), p.1255-1262

2016

Volltextzugriff (PDF)

Molecular profiling of myeloid progenitor cells in multi-mutated advanced systemic mastocytosis identifies KIT D816V as a distinct and late event

Leukemia, 2015-05, Vol.29 (5), p.1115-1122

2015

Volltextzugriff (PDF)

Splenomegaly, elevated alkaline phosphatase and mutations in the SRSF2/ASXL1/RUNX1 gene panel are strong adverse prognostic markers in patients with systemic mastocytosis

Leukemia, 2016-12, Vol.30 (12), p.2342-2350

2016

Volltextzugriff (PDF)

Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib

Leukemia, 2014-10, Vol.28 (10), p.1988-1992

2014

Volltextzugriff (PDF)

Cytogenetically cryptic ZMYM2-FLT3 and DIAPH1-PDGFRB gene fusions in myeloid neoplasms with eosinophilia

Leukemia, 2017-10, Vol.31 (10), p.2271-2273

2017

Volltextzugriff (PDF)

Long-term follow-up of treatment with imatinib in eosinophilia-associated myeloid/lymphoid neoplasms with PDGFR rearrangements in blast phase

Leukemia, 2013-11, Vol.27 (11), p.2254-2256

2013

Volltextzugriff (PDF)

Gene expression profiling of CD34+ cells identifies a molecular signature of chronic myeloid leukemia blast crisis

Leukemia, 2006-06, Vol.20 (6), p.1028-1034

2006

Volltextzugriff (PDF)

Centrosome aberrations in chronic myeloid leukemia correlate with stage of disease and chromosomal instability

Leukemia, 2005-07, Vol.19 (7), p.1192-1197

2005

Volltextzugriff (PDF)

MDR1 expression predicts outcome of Ph+ chronic phase CML patients on second-line nilotinib therapy after imatinib failure

Leukemia, 2014-07, Vol.28 (7), p.1478-1485

2014

Volltextzugriff (PDF)

Gene expression signature of primary imatinib-resistant chronic myeloid leukemia patients

Leukemia, 2006-08, Vol.20 (8), p.1400-1407

2006

Volltextzugriff (PDF)

Induction of centrosome and chromosome aberrations by imatinib in vitro

Leukemia, 2005-09, Vol.19 (9), p.1573-1578

2005

Volltextzugriff (PDF)

156 A NOVEL PCR-BASED ASSAY FOR TARGETED QUANTIFICATION OF DEL(5Q) IN MYELODYSPLASTIC SYNDROMES

Leukemia research, 2015-04, Vol.39, p.S80-S80

2015

Volltextzugriff (PDF)

65 MYELODYSPLASTIC SYNDROMES ARE CHARACTERIZED BY RECURRENT PATTERNS IN PATIENT-INDIVIDUAL MUTATIONAL HIERARCHIES THAT ARE SUBJECT TO HIGHLY DYNAMIC SUBCLONAL EVOLUTION DURING THERAPY AND DISEASE PROGRESSION

Leukemia research, 2015-04, Vol.39, p.S32-S32

2015

Volltextzugriff (PDF)

Expression of the p210BCR-ABL oncoprotein drives centrosomal hypertrophy and clonal evolution in human U937 cells

Leukemia, 2007-09, Vol.21 (9), p.1971-1976

2007

Volltextzugriff (PDF)

O-013 Mesenchymal stromal cells support significant engraftment of low-risk myelodysplastic syndromes (MDS) in a murine xenograft model

Leukemia research, 2013-05, Vol.37, p.S14-S14

2013

Volltextzugriff (PDF)

The KIT D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosis

Annals of hematology, 2014-01, Vol.93 (1), p.81-88

2014

Volltextzugriff (PDF)

Aneuploidy, the Primary Cause of the Multilateral Genomic Instability of Neoplastic and Preneoplastic Cells

IUBMB life, 2004-02, Vol.56 (2), p.65-81

2004

Volltextzugriff (PDF)

5-AZACYTIDINE IN COMBINATION WITH A NOVEL PAN-LYSYL OXIDASE INHIBITOR SYNERGISTICALLY RESTORES ERYTHROPOIESIS IN MYELODYSPLASTIC MALIGNANCIES

Leukemia research, 2023-05, Vol.128, p.107125, Article 107125

2023

Volltextzugriff (PDF)

Characterization of three new imatinib-responsive fusion genes in chronic myeloproliferative disorders generated by disruption of the platelet-derived growth factor receptor {beta} gene

Haematologica (Roma), 2007-02, Vol.92 (2), p.163-169

2007

Volltextzugriff (PDF)

The chromosomal basis of cancer

Analytical cellular pathology (Amsterdam), 2005, Vol.27 (5-6), p.293-318

2005

Volltextzugriff (PDF)

The EUROSKI biomarker study: Analyzing the mechanisms of treatment-free remission in chronic myeloid leukemia

Annals of oncology, 2017-09, Vol.28, p.v367-v367

2017

Volltextzugriff (PDF)

Cancer drug resistance: The central role of the karyotype

Drug resistance updates, 2007-02, Vol.10 (1), p.51-58

2007

Volltextzugriff (PDF)

1 – 25 von 207

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(199)
Mit Volltextzugriff
(197)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Englisch
(205)
Deutsch
(2)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV

Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)

Additional mutations in SRSF2, ASXL1 and/or RUNX1 identify a high-risk group of patients with KIT D816V+ advanced systemic mastocytosis

Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IV

Molecular profiling of myeloid progenitor cells in multi-mutated advanced systemic mastocytosis identifies KIT D816V as a distinct and late event

Splenomegaly, elevated alkaline phosphatase and mutations in the SRSF2/ASXL1/RUNX1 gene panel are strong adverse prognostic markers in patients with systemic mastocytosis

Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib

Cytogenetically cryptic ZMYM2-FLT3 and DIAPH1-PDGFRB gene fusions in myeloid neoplasms with eosinophilia

Long-term follow-up of treatment with imatinib in eosinophilia-associated myeloid/lymphoid neoplasms with PDGFR rearrangements in blast phase

Gene expression profiling of CD34+ cells identifies a molecular signature of chronic myeloid leukemia blast crisis

Centrosome aberrations in chronic myeloid leukemia correlate with stage of disease and chromosomal instability

MDR1 expression predicts outcome of Ph+ chronic phase CML patients on second-line nilotinib therapy after imatinib failure

Gene expression signature of primary imatinib-resistant chronic myeloid leukemia patients

Induction of centrosome and chromosome aberrations by imatinib in vitro

156 A NOVEL PCR-BASED ASSAY FOR TARGETED QUANTIFICATION OF DEL(5Q) IN MYELODYSPLASTIC SYNDROMES

65 MYELODYSPLASTIC SYNDROMES ARE CHARACTERIZED BY RECURRENT PATTERNS IN PATIENT-INDIVIDUAL MUTATIONAL HIERARCHIES THAT ARE SUBJECT TO HIGHLY DYNAMIC SUBCLONAL EVOLUTION DURING THERAPY AND DISEASE PROGRESSION

Expression of the p210BCR-ABL oncoprotein drives centrosomal hypertrophy and clonal evolution in human U937 cells

O-013 Mesenchymal stromal cells support significant engraftment of low-risk myelodysplastic syndromes (MDS) in a murine xenograft model

The KIT D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosis

Aneuploidy, the Primary Cause of the Multilateral Genomic Instability of Neoplastic and Preneoplastic Cells

5-AZACYTIDINE IN COMBINATION WITH A NOVEL PAN-LYSYL OXIDASE INHIBITOR SYNERGISTICALLY RESTORES ERYTHROPOIESIS IN MYELODYSPLASTIC MALIGNANCIES

Characterization of three new imatinib-responsive fusion genes in chronic myeloproliferative disorders generated by disruption of the platelet-derived growth factor receptor {beta} gene

The chromosomal basis of cancer

The EUROSKI biomarker study: Analyzing the mechanisms of treatment-free remission in chronic myeloid leukemia

Cancer drug resistance: The central role of the karyotype

Suchergebnisse filtern